JP2013536807A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536807A5
JP2013536807A5 JP2013526337A JP2013526337A JP2013536807A5 JP 2013536807 A5 JP2013536807 A5 JP 2013536807A5 JP 2013526337 A JP2013526337 A JP 2013526337A JP 2013526337 A JP2013526337 A JP 2013526337A JP 2013536807 A5 JP2013536807 A5 JP 2013536807A5
Authority
JP
Japan
Prior art keywords
cancer
alkyl
tumor
compound according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526337A
Other languages
English (en)
Japanese (ja)
Other versions
JP6039559B2 (ja
JP2013536807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/003949 external-priority patent/WO2012028243A1/en
Publication of JP2013536807A publication Critical patent/JP2013536807A/ja
Publication of JP2013536807A5 publication Critical patent/JP2013536807A5/ja
Application granted granted Critical
Publication of JP6039559B2 publication Critical patent/JP6039559B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526337A 2010-09-02 2011-08-05 Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体 Expired - Fee Related JP6039559B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10009117 2010-09-02
EP10009117.2 2010-09-02
PCT/EP2011/003949 WO2012028243A1 (en) 2010-09-02 2011-08-05 Pyrazolopyridinone derivatives as lpa receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013536807A JP2013536807A (ja) 2013-09-26
JP2013536807A5 true JP2013536807A5 (enExample) 2014-09-18
JP6039559B2 JP6039559B2 (ja) 2016-12-07

Family

ID=44532738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526337A Expired - Fee Related JP6039559B2 (ja) 2010-09-02 2011-08-05 Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体

Country Status (10)

Country Link
US (2) US8859775B2 (enExample)
EP (1) EP2611808B1 (enExample)
JP (1) JP6039559B2 (enExample)
CN (1) CN103189378B (enExample)
AR (1) AR082880A1 (enExample)
AU (1) AU2011297961B2 (enExample)
CA (1) CA2809892C (enExample)
ES (1) ES2530345T3 (enExample)
IL (1) IL225015A (enExample)
WO (1) WO2012028243A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
DK2882715T3 (en) 2012-05-18 2017-02-13 Sanofi Sa PYRAZOL DERIVATIVES AND USE THEREOF AS LPAR5 ANTAGONISTS
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
ES2563861T3 (es) 2012-06-14 2016-03-16 Daiichi Sankyo Company, Limited Derivado de piperidinilpirazolopiridina
PL2900669T3 (pl) * 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
WO2015050148A1 (ja) * 2013-10-04 2015-04-09 第一三共株式会社 ３－アリールピラゾロピリジン誘導体
WO2015076353A1 (ja) * 2013-11-25 2015-05-28 第一三共株式会社 ３－アルキルピラゾロピリジン誘導体
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
WO2015087996A1 (ja) * 2013-12-13 2015-06-18 第一三共株式会社 イミダゾピリジン誘導体
WO2015087995A1 (ja) * 2013-12-13 2015-06-18 第一三共株式会社 シクロアルキル又はヘテロシクリルピラゾロピリジン誘導体
KR20160096612A (ko) * 2013-12-13 2016-08-16 다이이찌 산쿄 가부시키가이샤 5-하이드록시-4-(트리플루오로메틸)피라졸로피리딘 유도체
WO2015102856A1 (en) * 2013-12-30 2015-07-09 Rxbio Inc. Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
WO2015111545A1 (ja) * 2014-01-21 2015-07-30 第一三共株式会社 縮合ピラゾール誘導体
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
TWI713534B (zh) * 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AU2016324483B2 (en) 2015-09-18 2021-07-29 Memorial Sloan Kettering Cancer Center Methods and compositions of inhibiting DCN1-UBC12 interaction
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
RU2742608C2 (ru) * 2016-04-14 2021-02-09 Марс, Инкорпорейтед Способы идентификации модуляторов gpr92
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
KR20200138202A (ko) 2018-03-30 2020-12-09 다이이찌 산쿄 가부시키가이샤 Lcat 결손증 치료약
CN108558876B (zh) * 2018-05-28 2020-08-04 中南大学 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用
CN108379275B (zh) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 溶血磷脂酸、溶血磷脂酸受体3以及溶血磷脂酸受体3激动剂的应用
EP3846640A1 (en) 2018-09-07 2021-07-14 Mars Incorporated Compounds that modulate gpr92 receptor activity and pet food products containing the same
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US12409171B2 (en) 2019-06-20 2025-09-09 University Of Kentucky Research Foundation Pharmaceutically active pyrazolo-pyridone modulators of DCN1/2-mediated cullin neddylation
US20230061417A1 (en) * 2019-12-12 2023-03-02 Chiesi Farmaceutici S.P.A. Thienopyrimidine derivatives as lpa receptor 2 inhibitors
US12404270B2 (en) 2019-12-12 2025-09-02 Chiesi Farmaceutici S.P.A. Quinazoline derivatives as LPA receptor 2 inhibitors
JP2023505703A (ja) 2019-12-12 2023-02-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体
ES2991765T3 (es) 2020-07-16 2024-12-04 Chiesi Farm Spa Derivados del ácido amido ciclohexano como inhibidores del receptor de LPA
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
US20240190860A1 (en) 2021-03-24 2024-06-13 Chiesi Farmaceutici S.P.A. 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
US20250066341A1 (en) 2021-12-23 2025-02-27 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
WO2023170025A1 (en) 2022-03-08 2023-09-14 Chiesi Farmaceutici S.P.A. Amido cyclopropyl derivatives as lpa receptor inhibitors
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CA2525245C (en) * 2003-06-27 2010-10-19 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
JP5048333B2 (ja) 2003-10-09 2012-10-17 ユニバーシティ オブ テネシー リサーチ ファウンデーション Ｌｐａ受容体アゴニストおよびアンタゴニストならびに使用法
EP1750722A4 (en) 2004-05-06 2010-03-10 Univ Virginia NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
WO2007139946A2 (en) * 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors

Similar Documents

Publication Publication Date Title
AR082880A1 (es) Derivados de pirazolopiridinona como antagonistas del receptor de lpa
JP2024522373A5 (enExample)
JP5826961B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類
CN102985421B (zh) 作为pi3k抑制剂用于治疗癌症和免疫-炎性疾病的萘啶衍生物
JP2019519503A5 (enExample)
JP2020508302A5 (enExample)
JP2013502404A (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
JP2010155845A (ja) 抗腫瘍薬組み合わせ
JP2010522152A5 (enExample)
JP2014534200A5 (enExample)
JP2020510032A5 (enExample)
JP2012505871A5 (enExample)
JP2024519188A5 (enExample)
JP2012502965A5 (enExample)
JP2007529426A5 (enExample)
RU2017142005A (ru) 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора
JP2018115209A (ja) がん幹細胞を標的とするための新規の化合物および組成物
JP2007533635A5 (enExample)
JP2020534300A5 (enExample)
CN102917703B (zh) 新型ep4激动剂
TWI694986B (zh) 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途
JP2019522681A5 (enExample)
CN106084237B (zh) 一种聚磷酸酯-聚乳酸两嵌段共聚物及其制备方法和载药胶束
JP2004521126A5 (enExample)
CN115867542A (zh) 新型苯并咪唑化合物